Zimmer Biomet’s Dental And Spine Spin-Off Will Be Called ZimVie
The company also named ZimVie’s management team, led by CEO Vafa Jamali.
You may also be interested in...
Zimmer Biomet’s CEO Bryan Hanson expects the spin-off will help streamline the company and optimize resources for innovation.
On Target Laboratories’ Cytalux (pafolacianine) is now approved for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.
Jeannette Bankes, the general manager of Alcon’s global surgical business, talked to Medtech Insight about how the company is addressing the cataract surgery market with a range of intraocular lenses intended to return the patients vision to as close to its natural optimal function as possible.